By partnering with Dendrite Clinical Systems, you could recover your R&D costs

When medical companies, hospitals, and societies choose a clinical registry provider, they look for data excellence. But what if your choice in registry software could also trigger a substantial cash injection for your organisation? By partnering with Dendrite Clinical Systems, clients gain more than a world-class platform for longitudinal studies, they could unlock a HMRC research and development (R&D) tax relief.

Under HMRC rules, tracking long-term outcomes to resolve clinical uncertainties, such as proving or disproving a clinical hypothesis, directly qualifies as R&D. Every year, our clients invest heavily in resolving these clinical unknowns. Through Dendrite’s specialized partner GKA Innovation, that exact investment can be leveraged to claim back non-dilutive government funding.

The financial rewards are highly compelling:

• 15% Cash Injection: Recover a net cash return of 15% on qualifying expenditures, including staff salaries, contractor fees, travel, software and data licenses.

• 20% EBITDA Boost: For smaller medical firms eyeing future buyouts, the relief improves your profit position by 20% of qualifying costs, significantly driving up acquisition valuation multiples.

• Look Back 2 Years: Claims operate retrospectively, allowing you to recoup expenses from the past two financial years.

Real-world Dendrite clients, including the Whiteley Clinic, have already successfully recovered substantial sums.

“We were introduced to GKA Innovations by Dr Peter Walton, the Managing Director of Dendrite. GKA came and reviewed our R&D activities with us, finding some areas we had been either underclaiming or failing to claim. They prepared an excellent report, and we received our R&D refund promptly. I would highly recommend GKA and will be using their services from this point onwards.” – Professor Mark Whiteley (Consultant Venous Surgeon and Consultant Phlebologist, and founder of The College of Phlebology and The Whiteley Clinic)

Working with Dendrite means your clinical data collection doubles as a government-backed financial asset. Choosing Dendrite isn’t just a clinical decision, it is a smart financial strategy that helps pay for itself.